Phase II study of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel for resectable esophageal squamous cell carcinoma. First-line (1L) tislelizumab (TIS) plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results